Cardiovascular morbi-mortality of 49 hemodialysis patients with high cardiovascular risk from 2015 to 2019 at the Donka national hemodialysis center

Secondary hyperparathyroidism (SHPTH) is a major complication in patients on maintenance hemodialysis burdened with high cardiovascular risk. Hypertension is also a high prevalence complication contributing to an increase in the mortality rate in hemodialysis patients. A possible association between SHPTH and hypertension has been widely reported in the literature and several pathogenetic mechanisms have been described. There is evidence that the decrease of plasma iPTH levels are correlated with hypertension correction in hemodialysis patients undergoing parathyroidectomy and oral calcimimetics administration. We have observed a similar behaviour also in a patient on chronic hemodialysis treated with Etelcalcetide. Even if this is an isolated observation, it could stimulate future investigation, possibly in dedicated clinical trials.

Download Full-text

Hyperuricemia as risk factor for cardiovascular disease – what’s new?

Medical alphabet ◽

10.33667/2078-5631-2020-13-5-11 ◽

2020 ◽

pp. 5-11

Author(s):

Yu. V. Zhernakova

Keyword(s):

Cardiovascular Disease ◽

Chronic Kidney Disease ◽

Uric Acid ◽

Cardiovascular Risk ◽

Epidemiological Studies ◽

Point Of View ◽

Medical Society ◽

High Cardiovascular Risk ◽

Management Algorithm ◽

Russian Medical

A significant number of epidemiological studies have shown that hyperuricemia is highly associated with the risk of developing cardiovascular disease, chronic kidney disease, and diabetes. In this connection, increased attention is required to monitor serum uric acid levels in patients, not only from a rheumatological point of view, but also with regard to reducing cardiovascular and renal risks. This article is a review of studies on the association of hyperuricemia with cardiovascular risk and a new consensus for the management of patients with hyperuricemia and high cardiovascular risk, published in december 2019 by a group of experts of the Russian Medical Society for Arterial Hypertension, which, among other things, includes a management algorithm of this category of patients.

Download Full-text

The effect of PCSK9 Inhibitor EVOLOCUMAB on aldosterone among high cardiovascular risk patients

Endocrine Abstracts ◽

10.1530/endoabs.70.ep124 ◽

2020 ◽

Author(s):

Elena Lzkhakov ◽

Yakov Shacham ◽

Mariana Yaron ◽

Merav Serebro ◽

Karen Tordjman ◽

...

Keyword(s):

Cardiovascular Risk ◽

High Cardiovascular Risk ◽

Pcsk9 Inhibitor ◽

Risk Patients

Download Full-text

Telmisartan in High Cardiovascular Risk Patients

European Cardiology Review ◽

10.15420/ecr.2012.8.1.10 ◽

2012 ◽

Vol 8 (1) ◽

pp. 10 ◽

Cited By ~ 1

Author(s):

Roland Asmar ◽

Keyword(s):

Cardiovascular Disease ◽

Cardiovascular Risk ◽

Ace Inhibitors ◽

Angiotensin Receptor Blockers ◽

High Cardiovascular Risk ◽

Raas Blockade ◽

Risk Patients ◽

Receptor Blockers ◽

Current Guidelines

The worldwide morbidity and mortality burden of cardiovascular disease (CVD) is overwhelming and caused by increasing life expectancy and an epidemic of risk factors, including hypertension. Therapeutic options targeting different areas of the renin–angiotensin–aldosterone system (RAAS) to disrupt pathophysiological processes along the cardiovascular continuum are available. Angiotensin-converting enzyme (ACE) inhibitors are first-line treatments for CVD and angiotensin receptor blockers (ARBs) are suitable alternatives. Both ACE inhibitors and ARBs prevent CVD by lowering blood pressure (BP). Additionally, several studies have demonstrated that RAAS blockade can reduce cardiovascular risk beyond what might be expected from BP lowering alone. However, the ARBs are not all equally effective. Telmisartan is a long-lasting ARB that effectively controls BP over the full 24-hour period. Recently, the Ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET) study showed that telmisartan reduces cardiovascular events in high cardiovascular risk patients similarly to the gold standard ACE inhibitor ramipril beyond BP lowering alone, but with a better tolerability. Based on the results of the ONTARGET and Telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) studies, telmisartan is indicated for the reduction of cardiovascular morbidity. This article aims to review current guidelines for the management of CVD and consider key data from clinical trials and clinical practice evaluating the role of telmisartan in CVD.

Download Full-text